Additionally, analysis of PTEN expression has been proposed as a complementary biomarker for mismatch repair status assessment in breast cancer, potentially contributing to the selection of patients, including those with a hormone receptor (HR) + tumor, eligible to immune-checkpoint blockade [4, 9]. The gene discussed is NR4A1; the disease is breast carcinoma.